Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency

Clinical characteristics.

Deficiency of very long-chain acyl-coenzyme A dehydrogenase (VLCAD), which catalyzes the initial step of mitochondrial beta-oxidation of long-chain fatty acids with a chain length of 14 to 20 carbons, is associated with three phenotypes. The severe early-onset cardiac and multiorgan failure form typically presents in the first months of life with hypertrophic or dilated cardiomyopathy, pericardial effusion, and arrhythmias, as well as hypotonia, hepatomegaly, and intermittent hypoglycemia. The hepatic or hypoketotic hypoglycemic form typically presents during early childhood with hypoketotic hypoglycemia and hepatomegaly, but without cardiomyopathy. The later-onset episodic myopathic form presents with intermittent rhabdomyolysis provoked by exercise, muscle cramps and/or pain, and/or exercise intolerance. Hypoglycemia typically is not present at the time of symptoms.

Diagnosis/testing.

The diagnosis of VLCAD deficiency is established in a proband with a specific pattern of abnormal acylcarnitine levels on biochemical testing and/or by identification of biallelic pathogenic variants in ACADVL on molecular genetic testing. If one ACADVL pathogenic variant is found and suspicion of VLCAD deficiency is high, specialized biochemical testing using cultured fibroblasts or lymphocytes may be needed for confirmation of the diagnosis.

Management.

Treatment of manifestations:

• Routine daily treatment. Low-fat formula or low long-chain fat / high medium-chain triglyceride (MCT) medical food, with 13%-39% of calories as total fat; total dietary protein above the dietary reference intake for age; MCT oil or triheptanoin supplementation; carnitine supplementation; consider supplementation with linoleic acid, arachidonic acid, alpha-linolenic acid, and docosahexaenoic acid; frequent feeding in infants and a bedtime snack high in complex carbohydrates in children and adults; nasogastric tube feeding for those with feeding issues; guided exercise and avoidance of severe exercise to address exercise intolerance in older individuals; standard treatment of cardiomyopathy; supportive developmental therapies as needed.
• Emergency outpatient treatment. Consider a trial outpatient treatment at home for up to 12 hours, including frequent high carbohydrate feedings, reduced fasting duration time, antipyretics, and antiemetics.
• Acute inpatient treatment. Administration of high-energy fluids (≥10% IV dextrose) with electrolytes at a rate of at least 1.5 times maintenance (minimum of 8 mg/kg/min of glucose) while avoiding the use of L-carnitine and IV lipids; standard treatment for cardiomyopathy / cardiac failure; ample hydration and alkalization of the urine for those with rhabdomyolysis.

Prevention of secondary complications: Acute rhabdomyolysis is treated with ample hydration and alkalization of the urine to protect kidney function and to prevent acute kidney failure secondary to myoglobinuria; if a surgery or procedure is required, notify designated metabolic center in advance of the procedure to discuss perioperative management with surgeons and anesthesiologists; some anesthetics may be contraindicated.

Surveillance: Measurement of growth parameters (including head circumference) and assessment of feeding skills (in infants/toddlers) at each visit; plasma carnitine panel, acylcarnitine profile, and creatine kinase level every three months for the first year of life, every three to six months for those between age one and seven years, and every six to 12 months for those older than age seven years; red blood cell or plasma essential fatty acids every six months for those on long-chain fat restriction; measurement of vitamins A, D, and E annually or as clinically indicated for those on long-chain fat restriction; echocardiogram at least annually or as clinically indicated; DXA scan every five years in adults; measurement of complete blood count, ferritin level, comprehensive metabolic panel, troponin, and B-type natriuretic protein as clinically indicated.

Agents/circumstances to avoid: Fasting; myocardial irritation; dehydration; high-fat diet; and volatile anesthetics and anesthetics that contain high doses of long-chain fatty acids such as propofol and etomidate.

Evaluation of relatives at risk: Evaluation of all at-risk sibs of any age is warranted to identify those who would benefit from treatment and preventive measures.

Pregnancy management: Labor and postpartum periods are catabolic states and place the mother at higher risk for rhabdomyolysis and subsequent myoglobinuria. A management plan for labor and delivery is necessary for the affected pregnant woman. In addition to regular assessment by a cardiologist and maternal fetal medicine specialist, the following are recommended: visit with a nutritionist familiar with VLCAD deficiency monthly or at least in each trimester; measurement of plasma carnitine panel (total, free, esters) and creatine kinase level at each visit; plasma acylcarnitine profile weekly to monthly; red blood cell or plasma essential fatty acids (for those on long-chain fat restriction) at least once during pregnancy; echocardiogram either prior to conception or as soon as a pregnancy is recognized; measurement of vitamins A, D, and E (for those on long-chain fat restriction), complete blood count, ferritin level, and metabolic panel as a baseline or as clinically indicated.

Genetic counseling.

VLCAD deficiency is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an ACADVL pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of inheriting neither of the familial pathogenic variants. Molecular genetic carrier testing for at-risk relatives and prenatal and preimplantation genetic testing are possible if the pathogenic variants in the family are known.

Suggestive Findings

Establishing the Diagnosis

The diagnosis of VLCAD deficiency is established in a proband with a specific pattern of abnormal acylcarnitine levels on biochemical testing and/or biallelic pathogenic (or likely pathogenic) variants in ACADVL identified on molecular genetic testing (see Table 1). If one ACADVL pathogenic variant is found and suspicion of VLCAD deficiency is high, specialized biochemical testing using cultured fibroblasts or lymphocytes may be needed for confirmation of the diagnosis.

Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variant" and "likely pathogenic variant" are synonymous in a clinical setting, meaning that both are considered diagnostic and can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this GeneReview is understood to include likely pathogenic variants. (2) Identification of biallelic ACADVL variants of uncertain significance (or of one known ACADVL pathogenic variant and one ACADVL variant of uncertain significance) does not establish or rule out the diagnosis.

Molecular Genetic Testing

Scenario 1: Abnormal NBS result. When NBS results and other laboratory findings suggest the diagnosis of VLCAD deficiency, molecular genetic testing approaches typically include single-gene testing. Sequence analysis of ACADVL is performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. Note: Depending on the sequencing method used, single-exon, multiexon, or whole-gene deletions/duplications may not be detected. If only one or no variant is detected by the sequencing method used, the next step is to perform gene-targeted deletion/duplication analysis to detect exon and whole-gene deletions or duplications.

Scenario 2: Genetic testing options for a symptomatic individual who has atypical findings associated with later-onset VLCAD deficiency or untreated infantile-onset VLCAD deficiency (resulting from NBS not performed or false negative NBS result) typically include a multigene panel or, less commonly, comprehensive genomic testing:

• A fatty acid oxidation or rhabdomyolysis multigene panel that includes ACADVL and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
  For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
• When the diagnosis of VLCAD deficiency has not been considered, comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is an option. Exome sequencing is most commonly used; genome sequencing is also possible.
  For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Table 1.

Molecular Genetic Testing Used in VLCAD Deficiency

Clinical Description

Depending on the severity of very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency, individuals can present with hypoketotic hypoglycemia, hepatomegaly, cardiomyopathy, and myopathy with recurrent rhabdomyolysis, triggered by a catabolic state. Therefore, the condition has been divided into three clinical subgroups, including a severe early-onset cardiac and multiorgan failure form, a hepatic or hypoketotic hypoglycemic form, and a later-onset myopathic form [Andresen et al 1999]. Most affected individuals identified by newborn screening (NBS) are asymptomatic at the time of diagnosis [Spiekerkoetter 2010, Baruteau et al 2013].

Scenario 1: Abnormal NBS result and prompt initiation of appropriate management in neonatal period. With early intensive supportive care and diet modification (see Management), normal cognitive outcome has been reported.

• Developmental and intelligence quotient (IQ) scores were similar to those seen in the general population (developmental quotient / IQ ≥85) [Brown et al 2014, Landau et al 2017].
• However, motor and speech delays were reported [Waisbren et al 2013].

Both Pena et al [2016] and Vockley et al [2016] reported individuals who developed cardiomyopathy while being treated with a medium-chain triglyceride oil-based diet.

Bleeker et al [2019] and Marsden et al [2021] reported that NBS results in prevention of hypoglycemic events in those with some residual enzyme activity, but not prevention of hypoglycemia or cardiac complications in affected individuals with very low residual enzyme activity.

Scenario 2: Symptomatic individual associated with later-onset VLCAD deficiency or untreated infantile-onset VLCAD deficiency (resulting from NBS not performed or false negative NBS result)

• Severe early-onset cardiac and multiorgan failure VLCAD deficiency typically presents in the first months of life with hypertrophic or dilated cardiomyopathy, pericardial effusion, and arrhythmias, as well as hypotonia, hepatomegaly, and intermittent hypoglycemia.
  • Cardiomyopathy and arrhythmias are often lethal. Ventricular tachycardia, ventricular fibrillation, and atrioventricular block have been reported [Bonnet et al 1999].
  • Although the morbidity resulting from cardiomyopathy may be severe, cardiac dysfunction may be reversible with early intensive supportive care and diet modification.
  • Cox et al [1998] reported normal cognitive outcome at age four years in an affected individual diagnosed clinically with VLCAD deficiency who had severe hypertrophic cardiomyopathy at age five months.
• Hepatic or hypoketotic hypoglycemic VLCAD deficiency typically presents during early childhood with hypoketotic hypoglycemia and hepatomegaly (similar to medium-chain acyl-coenzyme A dehydrogenase deficiency) but without cardiomyopathy. Hypoglycemia and poor feeding during the newborn period have been reported in neonates who were later diagnosed with VLCAD deficiency [Pena et al 2016].
• Later-onset episodic myopathic VLCAD deficiency, probably the most common phenotype, presents with intermittent rhabdomyolysis provoked by exercise, muscle cramps and/or pain, and/or exercise intolerance. Hypoglycemia typically is not present at the time of symptom onset in these individuals. Ascertainment in adulthood has been reported [Hoffman et al 2006].

Genotype-Phenotype Correlations

As a general rule, strong genotype-phenotype correlations exist in VLCAD deficiency [Andresen et al 1999]:

• Severe disease is associated with no residual enzyme activity, often resulting from null variants. Approximately 81% of pathogenic truncating variants in ACADVL are associated with the severe early-onset form [Andresen et al 1999].
• A specific homozygous missense pathogenic variant (c.709T>C;p.Cys237Arg) leading to low long-chain fatty acid oxidation flux may also be associated with cardiac disease [Diekman et al 2015].
• Milder childhood and adult forms are often associated with residual enzyme activity. The common p.Val283Ala variant, in both homozygous and compound heterozygous genotypes, is typically associated with the non-cardiac phenotypes [Spiekerkoetter et al 2009, Diekman et al 2015, Miller et al 2015].

Prevalence

Complete ascertainment by NBS is not assured, but the incidence of VLCAD deficiency is now estimated at 1:30,000 to 1:100,000 births.

NBS has demonstrated that VLCAD deficiency is more prevalent than previously suspected; however, the majority of children ascertained by NBS are asymptomatic during the first few years of observation, suggesting that these individuals may have gone undiagnosed prior to the advent of population-based screening.

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with VLCAD deficiency, the evaluations summarized in Tables 4 or 5 (depending on the age at diagnosis) are recommended, if not previously performed as part of the evaluation that led to the diagnosis.

Table 4.

Recommended Evaluations Following Initial Diagnosis of VLCAD Deficiency in a Neonate or Infant

Table 5.

Recommended Evaluations Following Initial Diagnosis of VLCAD Deficiency in an Older Child or Adult

Treatment of Manifestations

Frequently updated, succinct emergency care plans should detail the typical clinical issues (either those already experienced by the affected individual or those anticipated based on the diagnosis) and the importance of early management (e.g., use of IV glucose as an energy source, monitoring for cardiac rhythm disturbance, and monitoring of rhabdomyolysis) and avoidance of triggers (fasting, long-chain fats, and irritation of the myocardium) [Arnold et al 2009].

Cardiac dysfunction may be reversible with early, intensive supportive care (occasionally including extracorporeal membrane oxygenation) and diet modification.

Triheptanoin (C7). This odd medium-chain fatty acid was approved by the FDA in June 2020 for the treatment of pediatric and adult individuals with VLCAD deficiency.

• The use of triheptanoin is based on its action as an anaplerotic molecule that can correct the secondary depletion of TCA cycle intermediates occurring in these disorders.
• Benefits include decrease in total days of hospitalization per year and reduction in episodes of rhabdomyolysis [Roe & Brunengraber 2015, Zöggeler et al 2021]. Improvement in cardiomyopathy, hepatomegaly, and hypoglycemia was reported in those treated with triheptanoin compared to pretreatment [Roe & Brunengraber 2015, Vockley et al 2015, Vockley et al 2016, Gillingham et al 2017, Vockley et al 2017, Calvert et al 2018].
• Triheptanoin was less effective in reducing rhabdomyolysis post treatment compared to its effect on other symptoms of VLCAD deficiency, suggesting a role for other pathophysiologic mechanisms and demonstrating the need for additional therapies (see Therapies Under Investigation) [Sklirou et al 2021].
• Adverse events in all of the clinical trials were similar for C7 and C8 treatment and predominantly consisted of gastrointestinal symptoms (abdominal pain, diarrhea) [Sklirou et al 2021, Zöggeler et al 2021].

Table 6.

Routine Daily Treatment in Individuals with VLCAD Deficiency

Table 7.

Baseline ¹ Recommended Total, Long-Chain, and Medium-Chain Fat Intake and Estimated Energy Requirement By Age and Pregnancy/Lactation Status in Individuals with VLCAD Deficiency

Table 8.

Emergency Outpatient Treatment in Individuals with VLCAD Deficiency

Table 9.

Acute Inpatient Treatment in Individuals with VLCAD Deficiency ¹

Transitional care from pediatric to adult-centered multidisciplinary care settings. As a lifelong disorder with varying implications according to age, smooth transition of care from the pediatric setting is essential for long-term management and should be organized as a well-planned, continuous, multidisciplinary process integrating resources of all relevant subspecialties. Standardized procedures for transitional care do not exist for VLCAD deficiency because of the absence of multidisciplinary outpatient departments.

• Transitional care concepts have been developed in which adult internal medicine specialists initially see individuals with VLCAD deficiency together with pediatric metabolic experts, dietitians, psychologists, and social workers.
• As the long-term course of pediatric metabolic diseases in this age group is not yet fully characterized, continuous supervision by a center of expertise with metabolic diseases with sufficient resources is essential.

Prevention of Primary Manifestations

See Management, Treatment of Manifestations, Table 6.

Prevention of Secondary Complications

One of the most important components of management (as it relates to prevention of secondary complications) is education of parents and caregivers such that diligent observation results in management that can be administered expediently in the setting of intercurrent illness or other catabolic stressors.

Table 10.

Prevention of Secondary Manifestations in Individuals with VLCAD Deficiency

Surveillance

In addition to regular evaluations by a metabolic specialist and metabolic dietician, the surveillance evaluations summarized in Table 11 are recommended.

Table 11.

Recommended Surveillance for Individuals with VLCAD Deficiency

Agents/Circumstances to Avoid

Avoid the following:

• Fasting, including periods of preparation and recovery from planned surgery or sedation [Vellekoop et al 2011]
• Myocardial irritation (e.g., cardiac catheterization)
• Dehydration (risk for acute tubular necrosis)
• High-fat diet (long-chain fats) including ketogenic or carbohydrate-restricted diets for the purpose of weight loss. Careful weight reduction has been accomplished by restricting long-chain fats and calories, supplementing with calories provided through medium-chain triglycerides, and limiting overnight catabolism with uncooked cornstarch [Zweers et al 2012].
• Volatile anesthetics and anesthetics that contain high doses of long-chain fatty acids such as propofol and etomidate [Vellekoop et al 2011]. However, the use of propofol for short-duration procedures has been evaluated in individuals with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency and was not found to cause adverse events [Martin et al 2014].

Evaluation of Relatives at Risk

Testing of all at-risk sibs of any age is warranted to identify as early as possible those who would benefit from institution of treatment and preventive measures (see Management, Treatment of Manifestations).

• If the pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.
• If the pathogenic variants in the family are not known, plasma or dried blood spot acylcarnitine analysis may not be sufficiently sensitive, and direct VLCAD assay of lymphocytes or fatty acid oxidation probe studies of cultured fibroblasts may be required.

For at-risk newborn sibs when prenatal testing was not performed: in parallel with newborn screening either test for the familial ACADVL pathogenic variants or measure an acylcarnitine profile.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

During pregnancy, placental and fetal beta-oxidation may temporize or even improve maternal fatty acid beta-oxidation [Mendez-Figueroa et al 2010]. However, labor and postpartum periods are catabolic states and place the mother at higher risk for rhabdomyolysis and subsequent myoglobinuria. A management plan for labor and delivery has been proposed by Mendez-Figueroa et al [2010].

Energy needs and fat intake recommendations for women who are pregnant or lactating are listed in Table 7.

Table 12.

Recommended Surveillance for Pregnant and Lactating Women with VLCAD Deficiency

See MotherToBaby for further information on medication use during pregnancy.

Therapies Under Investigation

Bezafibrates. Small clinical trials have demonstrated controversial results.

• An open-label clinical trial showed continuously improving physical functioning as assessed through quality of life questionnaire scores in all affected individuals who participated [Shiraishi et al 2019].
• An in vitro study found that mitochondrial metabolic capacity and glutathione were affected by benzafibrate treatment [Lund et al 2021].

Dodecanedioic acid. In an in vitro study, dodecanedioic acid supplementation reduced levels of toxic very long-chain acylcarnitines [Radzikh et al 2021].

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.

Mode of Inheritance

Very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency is inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

• The parents of an affected child are presumed to be heterozygous for an ACADVL pathogenic variant.
• Molecular genetic testing is recommended for the parents of a proband to confirm that both parents are heterozygous for an ACADVL pathogenic variant and to allow reliable recurrence risk assessment.
• If a pathogenic variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, it is possible that one of the pathogenic variants identified in the proband occurred as a de novo event in the proband or as a postzygotic de novo event in a mosaic parent [Jónsson et al 2017]. If the proband appears to have homozygous pathogenic variants (i.e., the same two pathogenic variants), additional possibilities to consider include:
  • A single- or multiexon deletion in the proband that was not detected by sequence analysis and that resulted in the artifactual appearance of homozygosity;
  • Uniparental isodisomy for the parental chromosome with the pathogenic variant that resulted in homozygosity for the pathogenic variant in the proband.
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Sibs of a proband

• If both parents are known to be heterozygous for an ACADVL pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of inheriting neither of the familial pathogenic variants.
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Offspring of a proband. Unless an affected individual's reproductive partner also has VLCAD deficiency or is a carrier, offspring will be obligate heterozygotes (carriers) for a pathogenic variant in ACADVL.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of an ACADVL pathogenic variant.

Carrier Detection

Molecular genetic carrier testing for at-risk relatives requires prior identification of the ACADVL pathogenic variants in the family.

Biochemical genetic testing. Measurement of acylcarnitines (an acylcarnitine profile), particularly in an unstressed individual, is not reliable for identifying heterozygotes. Functional testing of fibroblasts, using the various protocols of palmitate oxidation and incorporation into small acylcarnitine species, also does not typically identify carriers. A direct VLCAD enzyme assay may provide better evidence of a carrier state than the options described previously, but in most cases molecular genetic testing is preferred. In addition, the clinical availability of the VLCAD enzyme assay has varied with time.

Related Genetic Counseling Issues

The genetic status of full sibs should be determined since many individuals with VLCAD deficiency are not symptomatic during early childhood. See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis, treatment, and preventive measures.

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

DNA banking. Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see Huang et al [2022].

Prenatal Testing and Preimplantation Genetic Testing

Molecular genetic testing. Once the ACADVL pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Biochemical genetic testing. Prenatal diagnosis of VLCAD deficiency based on the pattern of incorporation of labeled carbons (ranging from palmitate into shorter-chain acylcarnitines) by cultured amniocytes (similar to the fibroblast in vitro acylcarnitine profile) has been described. Assay of VLCAD enzyme activity can distinguish between affected and unaffected cells. Absence of immunoreactive VLCAD on western blot analysis in those with severe VLCAD deficiency should provide additional information. As experience with and clinical availability of these assays is limited in the United States, molecular genetic testing is preferred for prenatal testing.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

Molecular Pathogenesis

The fatty acid oxidation (FAO) spiral is a series of four reactions occurring in the mitochondrial matrix. Very long-chain acyl-coenzyme A dehydrogenase (VLCAD) catalyzes the initial step of mitochondrial beta-oxidation (β-oxidation) of long-chain fatty acids with a chain length of 14 to 20 carbons. There are a total of four highly homologous, straight-chain acyl-coenzyme A (CoA) dehydrogenases with differing, but overlapping, substrate specificities:

• Short (SCAD; uses C4-C6 fatty acyl-CoAs)
• Medium (MCAD; C6-C10 fatty acyl-CoAs)
• Long (LCAD; C10-C14 fatty acyl-CoAs)
• Very long (VLCAD; C14-C20 fatty acyl-CoAs)

SCAD, MCAD, and LCAD are homotetramers localized to the mitochondrial matrix; VLCAD is a homodimer associated with the inner mitochondrial membrane. These four homologs share about 40% amino acid identity or similarity within the catalytic domain; all use flavin adenine dinucleotide as the electron-accepting cofactor. Electrons are fed into the electron transport chain via ETF and ETF dehydrogenase.

With every turn of the β-oxidation spiral, the chain length is shortened by two carbon atoms. Reactions distal to the long-chain acyl-CoA dehydrogenase (LCAD) include those catalyzed by the long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) / trifunctional protein, including a hydratase step, dehydrogenase step, and thiolase step.

As one of the first enzymes in the FAO spiral, the enzyme VLCAD controls a critical point in the supply of electrons to the respiratory chain, and also provides a pathway permissive to the production of ketones. It would be expected that significant reduction at this step of fatty acid oxidation would impair the ability to transition successfully from fetal to neonatal life, maintain cardiac output, adapt to long fasting, and generate energy for exercise.

Mechanism of disease causation. Loss of function

Table 13.

Notable ACADVL Pathogenic Variants

Author History

Jessica A Connor, MS; Counsyl, Inc (2014-2017)
Nancy D Leslie, MD (2009-present)
Sofia Saenz-Ayala, MD (2022-present)
Kerry Shooner, MS, CGC; Cincinnati Children's Hospital Medical Center (2009-2014)
Arnold W Strauss, MD; Cincinnati Children's Hospital Medical Center (2009-2022)
Brad T Tinkle, MD, PhD; Cincinnati Children's Hospital Medical Center (2009-2014)
C Alexander Valencia, PhD; Cincinnati Children's Hospital Medical Center (2014-2022)
Kejian Zhang, MD, MBA; Cincinnati Children's Hospital Medical Center (2009-2022)

Revision History

• 13 July 2023 (nl) Revision: C14:1 level unit of measurement corrected to µmol/L in Suggestive Findings
• 16 June 2022 (ma) Comprehensive update posted live
• 4 January 2018 (ha) Comprehensive update posted live
• 11 September 2014 (me) Comprehensive update posted live
• 22 September 2011 (me) Comprehensive update posted live
• 28 May 2009 (me) Review posted live
• 29 December 2008 (ks) Original submission

Literature Cited

• Andresen BS, Olpin S, Poorthuis B, Scholte H, Vianey-Saban C, Wanders R, Ijlst L, Morris A, Pourfarzam M, Bartlett K, Baumgartner R, deKlerk J, Schroeder L, Corydon T, Lund H, Winter V, Bross P, Bolund L, Gregersen N (1999) Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 64:479-94 [PMC free article: PMC1377757] [PubMed: 9973285]

• Arnold GL, Van Hove J, Freedenberg D, Strauss A, Longo N, Burton B, Garganta C, Ficicioglu C, Cederbaum S, Harding C, Boles RG, Matern D, Chakraborty P, Feigenbaum A (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85-90. [PMC free article: PMC3219055] [PubMed: 19157942]

• Baruteau J, Sachs P, Broué P, Brivet M, Abdoul H, Vianey-Saban C, Ogier de Baulny H. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36:795-803. [PubMed: 23053472]

• Behrend AM, Harding CO, Shoemaker JD, Martern D, Sahn DJ, Elliot DL, Gillingham MB (2012) Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation. Mol Genet Metab 105:110-5. [PMC free article: PMC3253922] [PubMed: 22030098]

• Bleeker JC, Kok IL, Ferdinandusse S, van der Pol WL, Cuppen I, Bosch AM, Langeveld M, Derks TGJ, Williams M, de Vries M, Mulder MF, Gozalbo ER, de Sain-van der Velden MGM, Rennings AJ, Schielen PJCI, Dekkers E, Houtkooper RH, Waterham HR, Pras-Raves ML, Wanders RJA, van Hasselt PM, Schoenmakers M, Wijburg FA, Visser G. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. J Inherit Metab Dis. 2019;42:414-23. [PubMed: 30761551]

• Bonnet D, Martin D, De Lonlay P, Villain E, Jouvet P, Rabier D, Brivet M, Saudubray JM (1999) Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 100:2248-53 [PubMed: 10577999]

• Brown A, Crowe L, Andresen BS, Anderson V, Boneh A. Neurodevelopmental profiles of children with very long chain acyl-CoA dehydrogenase deficiency diagnosed by newborn screening. Mol Genet Metab. 2014;113:278-82. [PubMed: 25456746]

• Calvert S, Barwick K, Par M, Ni Tan K, Borges K. A pilot study of add-on oral triheptanoin treatment for children with medically refractory epilepsy. Eur J Paediatr Neurol. 2018;22:1074-80. [PubMed: 30126760]

• Cox GF, Souri M, Aoyama T, Rockenmacher S, Varvogli L, Rohr F, Hashimoto T, Korson MS. Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr. 1998;133:247-53. [PubMed: 9709714]

• Diekman E, de Sain-van der Velden M, Waterham H, Kluijtmans L, Schielen P, van Veen EB, Ferdinandusse S, Wijburg F, Visser G. The newborn screening paradox: sensitivity vs. overdiagnosis in VLCAD deficiency. JIMD Rep. 2016;27:101-6. [PMC free article: PMC4864775] [PubMed: 26453363]

• Diekman EF, Ferdinandusse S, van der Pol L, Waterham HR, Ruiter JP, Ijlst L, Wanders RJ, Houten SM, Wijburg FA, Blank AC, Asselbergs FW, Houtkooper RH, Visser G. Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency. Genet Med. 2015;17:989-94. [PubMed: 25834949]

• Evans M, Andresen BS, Nation J, Boneh A. VLCAD deficiency: follow-up and outcome of patients diagnosed through newborn screening in Victoria. Mol Genet Metab. 2016;118:282-7. [PubMed: 27246109]

• Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, Deward S, Lasarev MR, Pollaro J, DeLany JP, Burchill LJ, Goodpaster B, Shoemaker J, Matern D, Harding CO, Vockley J. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40:831-43. [PMC free article: PMC6545116] [PubMed: 28871440]

• Gillingham MB, Scott B, Elliott D, Harding CO (2006) Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 89:58-63 [PMC free article: PMC2706834] [PubMed: 16876451]

• Hall PL, Marquardt G, McHugh DMS, Currier RJ, Tang H, Stoway DS, Rinaldo P (2014) Post-analytical tool improve performance of newborn screening by tandem mass spectrometry. Genet Med.16:889-95. [PMC free article: PMC4262759] [PubMed: 24875301]

• Hall PL, Wittenauer A, Hagar A. post-analytical tools for the triage of newborn screening results in follow-up can reduce confirmatory testing and guide performance improvement. Int J Neonatal Screen. 2020;6:20. [PMC free article: PMC7422973] [PubMed: 33073017]

• Hesse J, Brau C, Behringer S, Spiekerkoetter U, Tucci S. The diagnostic challenge in very-long chain acyl-CoA dehydrogenase deficiency (VLCADD). J Inherit Metab Dis 2018;41:1169-78. [PubMed: 30194637]

• Hoffman JD, Steiner RD, Paradise L, Harding CO, Ding L, Strauss AW, Kaplan P (2006) Rhabdomyolysis in the military: recognizing late-onset very long-chain acyl CoA dehydrogenase deficiency. Mil Med 171:657-8 [PubMed: 16895136]

• Huang SJ, Amendola LM, Sternen DL. Variation among DNA banking consent forms: points for clinicians to bank on. J Community Genet. 2022;13:389-97. [PMC free article: PMC9314484] [PubMed: 35834113]

• Institute of Medicine. Dietary fats: total fat and fatty acids. In: Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: The National Academies Press; 2005:422-541.

• Jónsson H, Sulem P, Kehr B, Kristmundsdottir S, Zink F, Hjartarson E, Hardarson MT, Hjorleifsson KE, Eggertsson HP, Gudjonsson SA, Ward LD, Arnadottir GA, Helgason EA, Helgason H, Gylfason A, Jonasdottir A, Jonasdottir A, Rafnar T, Frigge M, Stacey SN, Th Magnusson O, Thorsteinsdottir U, Masson G, Kong A, Halldorsson BV, Helgason A, Gudbjartsson DF, Stefansson K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature. 2017;549:519-22. [PubMed: 28959963]

• Laforêt P, Acquaviva-Bourdain C, Rigal O, Brivet M, Penisson-Besnier I, Chabrol B, Chaigne D, Boespflug-Tanguy O, Laroche C, Bedat-Millet AL, Behin A, Delevaux I, Lombès A, Andresen BS, Eymard B, Vianey-Saban C (2009) Diagnostic assessment and long-term follow-up of 13 patients with very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord 19:324-9 [PubMed: 19327992]

• Landau YE, Waisbren SE, Chan LM, Levy HL. Long-term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease. J Inherit Metab Dis. 2017;40:209-18. [PubMed: 28054209]

• Liebig M, Gyenes M, Brauers G, Ruiter JP, Wendel U, Mayatepek E, Strauss AW, Wanders RJ, Spiekerkoette U. Carnitine supplementation induces long-chain acylcarnitine production--studies in the VLCAD-deficient mouse. J Inherit Metab Dis. 2006;29:343-4. [PubMed: 16763898]

• Lund M, Andersen KG, Heaton R, Hargreaves IP, Gregersen N, Olsen R. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency. Biochim Biophys Acta Mol Basis Dis. 2021;1867:166100. [PubMed: 33549744]

• Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med. 2021;23:816-29. [PMC free article: PMC8105167] [PubMed: 33495527]

• Martin JM, Gillingham MB, Harding CO (2014) Use of propofol for short duration procedures in children with long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencies. Mol Genet Metab 112:139-42. [PMC free article: PMC4121654] [PubMed: 24780638]

• Mendez-Figueroa H, Shchelochkov OA, Shaibani A, Aagaard-Tillery K, Shinawi MS (2010) Clinical and biochemical improvement of very long-chain acyl-CoA dehydrogenase deficiency in pregnancy. J Perinatol 30:558-62. [PubMed: 20668464]

• Merritt JL 2nd, Vedal S, Abdenur JE, Au SM, Barshop BA, Feuchtbaum L, Harding CO Hermerath C, Lorey F, Sesser DE, Thompson JD, Yu A (2014) Infants suspected to have very-log chain acyl-CoA dehydrogenase deficiency from newborn screening. Mol Genet Metab 111:484-92. [PubMed: 24503138]

• Miller MJ, Burrage LC, Gibson JB, Strenk ME, Lose EJ, Bick DP, Elsea SH, Sutton VR, Sun Q, Graham BH, Craigen WJ, Zhang VW, Wong LJ. Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States. Mol Genet Metab. 2015;116:139-45. [PMC free article: PMC4790081] [PubMed: 26385305]

• Pena LD, van Calcar SC, Hansen J, Edick MJ, Walsh Vockley C, Leslie N, Cameron C, Mohsen AW, Berry SA, Arnold GL, Vockley J, IBEMC. Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database. Molecular genetics and metabolism. 2016;118:272-81. [PMC free article: PMC4970910] [PubMed: 27209629]

• Pervaiz MA, Kendal F, Hegde M, Singh RH. MCT oil-based diet reverses hypertrophic cardiomyopathy in a patient with very long chain acyl-CoA dehydrogenase deficiency. Indian J Hum Genet. 2011;17:29-32 [PMC free article: PMC3144685] [PubMed: 21814341]

• Radzikh I, Fatica E, Kodger J, Shah R, Pearce R, Sandlers YI. Metabolic outcomes of anaplerotic dodecanedioic acid supplementation in very long chain acyl-CoA dehydrogenase (VLCAD) deficient fibroblasts. Metabolites. 2021;11:538. [PMC free article: PMC8412092] [PubMed: 34436479]

• Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24. [PMC free article: PMC4544753] [PubMed: 25741868]

• Roe CR, Brunengraber H. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: review of 15 years experience. Mol Genet Metab. 2015;116:260-8. [PMC free article: PMC4712637] [PubMed: 26547562]

• Roe DS, Yang BZ, Vianey-Saban C, Struys E, Sweetman L, Roe CR (2006) Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts. Mol Genet Metab 87:40-7 [PubMed: 16297647]

• Shiraishi H, Yamada K, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey. Mol Genet Metab Rep. 2019;20:100496. [PMC free article: PMC6661278] [PubMed: 31372341]

• Sklirou E, Alodaib AN, Dobrowolski SF, Mohsen AA, Vockley J. Physiological perspectives on the use of triheptanoin as anaplerotic therapy for long chain fatty acid oxidation disorders. Front Genet. 2021;11:598760. [PMC free article: PMC7875087] [PubMed: 33584796]

• Solis JO, Singh RH (2002) Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc 102:1800-3 [PubMed: 12487544]

• Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis. 2010;33:527-32. [PubMed: 20449660]

• Spiekerkoetter U, Linder M, Santer R, Grotzke M, Baumgartner MR, Boehles H, Das A, Haase C, Hennemann JB, Karall D, de Klerk H, Knerr I, Koch HG, Plecko B, Roschinger W, Schwab KO, Scheible D, Wijburg FA, Zschocke J, Mayatepek E, Wendel U (2009) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498-505. [PubMed: 19452263]

• Van Calcar SC, Sowa M, Rohr F, Beazer J, Setlock T, Weihe TU, Pendyal S, Wallace LS, Hansen JG, Stembridge A, Splett P, Singh RH. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach. Mol Genet Metab. 2020;131:23-37. [PubMed: 33093005]

• Vellekoop P, Diekman EF, van Tuijl I, de Vries MMC, van Hasselt, PM, Visser G (2011) Perioperative measures in very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab. 103:96-7. [PubMed: 21333574]

• Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, Tanpaiboon P, Grunewald S, Murphy E, Bowden A, Chen W, Chen CY, Cataldo J, Marsden D, Kakkis E. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis. 2019;42:169-77. [PMC free article: PMC6348052] [PubMed: 30740733]

• Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, Tanpaiboon P, Grunewald S, Murphy E, Humphrey R, Mayhew J, Bowden A, Zhang L, Cataldo J, Marsden DL, Kakkis E (2017) UX007 for the treatment of long chain-fatty acid oxidation disorders: safety and efficacy in children and adults following 24 weeks of treatment. Mol Genet Metab. 120:370-7. [PubMed: 28189603]

• Vockley J, Charrow J, Ganesh J, Eswara M, Diaz GA, McCracken E, Conway R, Enns GM, Starr J, Wang R, Abdenur JE, Sanchez-de-Toledo J, Marsden DL (2016) Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab. 119:223-31. [PMC free article: PMC5083220] [PubMed: 27590926]

• Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, Kakkis E. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--a retrospective chart review. Mol Genet Metab. 2015;116:53-60. [PMC free article: PMC4561603] [PubMed: 26116311]

• Waisbren SE, Landau Y, Wilson J, Vockley J. Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. Dev Disabil Res Rev. 2013;17:260-8. [PMC free article: PMC4137760] [PubMed: 23798014]

• Zöggeler T, Stock K, Jörg-Streller M, Spenger J, Konstantopoulou V, Hufgard-Leitner M, Scholl-Bürgi S, Karall D. Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders. Orphanet J Rare Dis. 2021;16:28. [PMC free article: PMC7807521] [PubMed: 33446227]

• Zweers H, Timmer C, Rasmussen E, den Heijer M, de Valk H (2012) Successful weight loss in two adult patients diagnosed with late-onset long-chain fatty acid oxidation defect. JIMD Rep. 6:127-9. [PMC free article: PMC3565639] [PubMed: 23430950]